Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TBXAS1 | P24557 | 12/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.55 |
| ▸ | EGLN3 | Q9H6Z9 | 1/20 | 0.52 |
| ▸ | FDPS | P14324 | 2/20 | 0.51 |
| ▸ | GGPS1 | O95749 | 3/20 | 0.50 |
| ▸ | BTN3A1 | O00481 | 1/20 | 0.50 |
| ▸ | CA12 | O43570 | 1/20 | 0.50 |
| ▸ | CA2 | P00918 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | MMP2 | P08253 | 1/20 | 0.50 |
| ▸ | MMP9 | P14780 | 1/20 | 0.50 |
| ▸ | MMP8 | P22894 | 1/20 | 0.50 |
| ▸ | MMP14 | P50281 | 1/20 | 0.50 |
| ▸ | CA9 | Q16790 | 1/20 | 0.50 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.50 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.47 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4968502 | 0.85 | FDPS (0.51) | TBXAS1ALDH1A1EGLN3FDPSGGPS1 | |
| SCHEMBL10655960 | 0.81 | TBXAS1 (0.88) | TBXAS1EGLN3 | |
| SCHEMBL27461167 | 0.80 | TBXAS1 (0.67) | TBXAS1ALDH1A1EGLN3FDPSGGPS1 | |
| SCHEMBL11275678 | 0.79 | TBXAS1 (1.00) | TBXAS1 | |
| SCHEMBL4682917 | 0.78 | FDPS (0.52) | TBXAS1ALDH1A1EGLN3FDPSGGPS1 | |
| SCHEMBL4241305 | 0.78 | FDPS (0.56) | TBXAS1ALDH1A1EGLN3FDPSGGPS1 | |
| Hydrochloric Acid SCHEMBL11267409 | 0.77 | TBXAS1 (1.00) | TBXAS1 | |
| SCHEMBL2697302 | 0.77 | CYP11B1 (0.50) | TBXAS1ALDH1A1FDPSGGPS1BTN3A1 | |
| SCHEMBL19200881 | 0.74 | FDPS (0.49) | TBXAS1ALDH1A1EGLN3FDPSGGPS1 | |
| SCHEMBL11161842 | 0.74 | TBXAS1 (1.00) | TBXAS1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130131052-A1 | Amelioration Of The Development Of Cataracts And Other Ophthalmic Diseases | MATIER WILLIAM L (US) | 2013-05-23 | — | — | US | disclosed |
| US-20130131052-A1 | Amelioration Of The Development Of Cataracts And Other Ophthalmic Diseases | MATIER WILLIAM L (US) | 2013-05-23 | — | — | US | disclosed |
| US-8383648-B2 | Applying such as 1-oxyl-4-(3'-ethoxy-2',2'-dimethyl)propanecarbonyloxy-2,2,6,6-tetramethylpiperidine to eye surface; halting growth, preventing surgery | COLBY PHARMACEUTICAL COMPANY (US) | 2013-02-26 | — | — | US | disclosed |
| US-8383648-B2 | Applying such as 1-oxyl-4-(3'-ethoxy-2',2'-dimethyl)propanecarbonyloxy-2,2,6,6-tetramethylpiperidine to eye surface; halting growth, preventing surgery | COLBY PHARMACEUTICAL COMPANY (US) | 2013-02-26 | — | — | US | disclosed |
| US-8383648-B2 | Applying such as 1-oxyl-4-(3'-ethoxy-2',2'-dimethyl)propanecarbonyloxy-2,2,6,6-tetramethylpiperidine to eye surface; halting growth, preventing surgery | COLBY PHARMACEUTICAL COMPANY (US) | 2013-02-26 | — | — | US | disclosed |
| US-7825134-B2 | Amelioration of cataracts, macular degeneration and other ophthalmic diseases | OTHERA HOLDING, INC. (US) | 2010-11-02 | — | — | US | disclosed |
| US-7825134-B2 | Amelioration of cataracts, macular degeneration and other ophthalmic diseases | OTHERA HOLDING, INC. (US) | 2010-11-02 | — | — | US | disclosed |
| US-7825134-B2 | Amelioration of cataracts, macular degeneration and other ophthalmic diseases | OTHERA HOLDING, INC. (US) | 2010-11-02 | — | — | US | disclosed |
| US-20080274983-A1 | Amelioration Of The Development Of Cataracts And Other Ophthalmic Diseases | OTHERA HOLDING, INC. (US) | 2008-11-06 | — | — | US | disclosed |
| US-20080274983-A1 | Amelioration Of The Development Of Cataracts And Other Ophthalmic Diseases | OTHERA HOLDING, INC. (US) | 2008-11-06 | — | — | US | disclosed |
| US-20080274983-A1 | Amelioration Of The Development Of Cataracts And Other Ophthalmic Diseases | OTHERA HOLDING, INC. (US) | 2008-11-06 | — | — | US | disclosed |
| US-7442711-B2 | Amelioration of the development of cataracts and other ophthalmic diseases | OTHERA HOLDING, INC. (US) | 2008-10-28 | — | — | US | disclosed |
| US-7442711-B2 | Amelioration of the development of cataracts and other ophthalmic diseases | OTHERA HOLDING, INC. (US) | 2008-10-28 | — | — | US | disclosed |
| US-7442711-B2 | Amelioration of the development of cataracts and other ophthalmic diseases | OTHERA HOLDING, INC. (US) | 2008-10-28 | — | — | US | disclosed |
| US-20050131025-A1 | Amelioration of cataracts, macular degeneration and other ophthalmic diseases | COLBY PHARMACEUTICAL COMPANY | 2005-06-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080274983-A1 | Amelioration Of The Development Of Cataracts And Other Ophthalmic Diseases | C3AR1, C1R, AKR1C3 | TBXAS1 2070/4885ALDH1A1 756/4885EGLN3 1023/4885 |
| US-20130131052-A1 | Amelioration Of The Development Of Cataracts And Other Ophthalmic Diseases | C3AR1, C1R, AKR1C3 | TBXAS1 2070/4885ALDH1A1 756/4885EGLN3 1023/4885 |
| US-20050131025-A1 | Amelioration of cataracts, macular degeneration and other ophthalmic diseases | C1R, CRYAB, C9 | TBXAS1 2822/4885ALDH1A1 1080/4885EGLN3 1185/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.